Growing evidence shows that oncogenic mutations (e.g., BRAF and RAS mutations) cause numerous alterations in the expression of genes implicated in cell cycle control, migration, differentiation, and cancer stem cells, all of these are important for NSCLC pathogenesis and treatment resistance [23,24]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.